Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Hand-foot syndrome (HFS) is a well-known adverse event associated with capecitabine, a prodrug of 5-Fluorouracil (5-FU). HFS manifests as acral erythema, with swelling and dysesthesia of the palms and plantar aspects of the feet, which in the absence of dosage reduction or drug cessation, progresses to moist desquamation and ulceration, resulting in serious infections and loss of function. We report a case of HFS, with scleroderma-like changes, apparently induced by capecitabine. In our case, capecitabine, given in the recommended dosage was observed to lead to hyperpigmentation of the palms and soles, followed by a distinct keratoderma-like thickening unfamiliar to usual cases of HFS. This case may provide important clues for revising the definition of HFS, and allow the formation of effective preventive strategies for this side effect of chemotherapy.
Lee
Sehe-Dong
SD
Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea.
Kim
Hye-Jeong
HJ
Hwang
Seung-Jae
SJ
Kim
Yoon-Jung
YJ
Nam
Seung-Hyun
SH
Kim
Bong-Seog
BS
D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000175:diagnosis; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D012307:Risk Factors; D012594:Scleroderma, Localized / Q000139:chemically induced* / Q000175:diagnosis
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil